Sean P. Duffy, the chief executive officer of Omada Health, Inc. (NASDAQ:OMDA), has executed a significant divestment of company equity. Over a three-day window from June 24 to June 26, 2026, Duffy sold a total of 17,258 shares of Omada Health common stock. The aggregate value of these transactions reached $342,115. The shares were disposed of at prices varying between $19.0033 and $20.9 per share. These sales were carried out under the guidelines of a pre-arranged 10b5-1 trading plan, which Duffy originally established on March 13, 2026. The reported prices for certain transactions reflect the weighted average of multiple trades executed within specific price ranges on those dates.
Following these recent transactions, Duffy's direct ownership in Omada Health stands at 394,603 shares. Furthermore, he holds an additional 851,659 shares indirectly through family trusts. Duffy has formally disclaimed beneficial ownership of the shares held within these family trusts, limiting his claimed interest to his pecuniary stake. The stock currently trades at $20.89, indicating strong momentum with a 32% gain year-to-date. However, analysis from InvestingPro suggests the shares might be overvalued relative to their Fair Value estimate.
In the broader context of corporate activity, Omada Health recently reported its financial results for the first quarter of 2026. The company delivered a notable earnings surprise, achieving an earnings per share (EPS) of -$0.05, which exceeded the forecasted -$0.08. Revenue for the quarter reached $78 million, marking a significant 42% increase compared to the previous year. In addition to these financial results, Omada Health held its 2026 Annual Meeting of Stockholders. During this meeting, Sean Duffy and Trevor Fetter were elected as Class I Directors, with both set to serve until the 2029 annual meeting. Meanwhile, Citizens raised its price target for Omada Health to $21 from $18, maintaining a Market Outperform rating. Analyst Constantine Davides from Citizens noted the company's trading range and revenue estimates as factors in the decision. These developments reflect ongoing investor interest and confidence in Omada Health's growth trajectory.